Trial Profile
Tolerability, pharmacokinetics, and pharmacodynamics of apixabanin in volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Aug 2013
Price :
$35
*
At a glance
- Drugs Apixaban (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Stroke; Venous thromboembolism
- Focus Adverse reactions
- 15 Aug 2013 New trial record